S'abonner

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus - 12/08/11

Doi : 10.1016/j.jaad.2006.06.006 
Lasse R. Braathen, MD, PhD, MHA a, , Rolf-Markus Szeimies, MD, PhD b, Nicole Basset-Seguin, MD, PhD c, Robert Bissonnette, MD d, Peter Foley, MBBS, BMedSc, MD e, David Pariser, MD f, Rik Roelandts, MD, PhD g, Ann-Marie Wennberg, MD, PhD h, Colin A. Morton, MBChB, MD, FRCP i
a From Dermatological University Clinic, Bern 
b Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg 
c Institut de Recherche sur la Peau, Hôpital Saint-Louis, Paris 
d Innovaderm Research, Montreal 
e The University of Melbourne, Department of (Medicine) Dermatology, St Vincent Hospital Melbourne 
f Department of Dermatology, Eastern Virginia Medical School, and Virginia Clinical Research, Inc, Norfolk 
g Photodermatology Unit, University Hospital St Rafaël, Leuven 
h Department of Dermatology, Sahlgrenska University Hospital, Göteborg 
i Department of Dermatology, Falkirk Royal Infirmary 

Reprint requests: Lasse R. Braathen, MD, PhD, MHA, Dermatological University Clinic, Inselspital, 3010, Bern, Switzerland.

Bern, Switzerland; Regensburg, Germany; Paris, France; Montreal, Canada; Fitzroy, Australia; Norfolk, Virginia; Leuven, Belgium; Göteborg, Sweden; Falkirk, Scotland

Abstract

Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen’s disease, and basal cell carcinoma (superficial and nodular). This article presents up-to-date, practical, evidence-based recommendations on the use of topical PDT using 5-aminolevulinic acid or methyl aminolevulinate for the treatment (and prevention) of nonmelanoma skin cancers. A systematic literature review was conducted (using MEDLINE), and recommendations were made on the basis of the quality of evidence for efficacy, safety/tolerability, cosmetic outcome, and patient satisfaction/preference. Topical PDT is highly effective in the treatment of actinic keratoses, Bowen’s disease, superficial and thin nodular basal cell carcinomas, with cosmesis typically superior to that achieved with existing standard therapies. PDT may also be a means of preventing certain nonmelanoma skin cancers in immunosuppressed patients.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : AK, ALA, BCC, BD, MAL, nBCC, NMSC, PDT, sBCC, SCC


Plan


 The recommendations set forth in this article have been prepared for dermatologists on behalf of the International Society for Photodynamic Therapy in Dermatology and reflect the best data available at the time this report was prepared. Caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations of this report. It may be necessary or even desirable to depart from the recommendations in the interests of specific patients or special circumstances. Just as adherence to these recommendations may not constitute a defense against a claim of negligence, so deviation from them should not necessarily be deemed negligent.
Funding sources: The work of the IPDT was supported by an educational grant from Galderma International, Paris, France.
Disclosure: Dr Braathen has received speakers’ honoraria from Galderma International. He is currently a consultant for PhotoCure. The department of Dermatology, chaired by Dr Braathen, has received financial support from Galderma International and PhotoCure for performing clinical trials. Dr Szeimies received financial support for performing clinical trials, has served as a consultant for, and has received speakers’ honoraria from Galderma International. He has received financial support from Biocam GmbH, Energist, Medac, 3M, PhotoCure, Waldmann Medizintechnik, and Wavelight AG for performing clinical trials. Dr Basset-Seguin does consultant work for Galderma and has a consultancy agreement with 3M. Dr Bissonnette has served as a consultant and received research grants to conduct clinical trials from PhotoCure. He has received research grants to conduct basic and clinical trials from DUSA Pharmaceuticals, QLT Inc, and Quest Pharmatech. Dr Foley has been paid for PDT trials sponsored by PhotoCure ASA, Galderma, and QLT; and non-NMSC trials by Peplin and 3M. He has received honoraria and travel bureaux from PhotoCure and Galderma for presentations at national and international congresses and symposia and has received honoraria for attending meetings as a member of Galderma Australia’s Medical Advisory Board. He has acted as a consultant to Galderma Australia, 3M Australia, and Peplin. Dr Pariser has served as an investigator and consultant with Galderma International and an investigator with PhotoCure and DUSA Pharmaceuticals. Dr Wennberg has taken part in clinical trials with Galderma International, Photocure, 3M, and Fujisawa. She has received fees for giving lectures from Galderma International, PhotoCure, 3M, Fujisawa, and Schering Plough. Dr Morton has received financial support for performing clinical trials and speakers’ honoraria from Galderma. He has received travel scholarships from 3M, PhotoCure, and Phototherapeutics Ltd and has received support for performing clinical trials from PhotoCure and Schering AG.


© 2007  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 56 - N° 1

P. 125-143 - janvier 2007 Retour au numéro
Article précédent Article précédent
  • Acrodermatitis enteropathica and an overview of zinc metabolism
  • Emanual Maverakis, Maxwell A. Fung, Peter J. Lynch, Michelle Draznin, Daniel J. Michael, Beth Ruben, Nasim Fazel
| Article suivant Article suivant
  • Screening for melanoma
  • Warren R. Heymann

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.